xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

233

ICAR SINONASAL TUMORS

TABLE XXIII.B.2 Evidence surrounding sinonasal osteosarcoma.

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

Lowet al. 1282

Sinonasal OsS a : 14/14 OS

2020 4

Retrospective case series

1. Old age and advanced local extension are associated with worse prognosis 2. 1-, 3-, 5-, and 10-year OS: 85.1%, d 67.0%, d 47.9%, d and35.9%, d respectively

Kontio et al. 1281

Sinonasal OsS a : 11/20 Recurrence rate 1. Surgery is the mainstay of treatment in craniofacial OsS 2. Adjuvant RT is indicated in case of involved/close margins

2019 4

Retrospective case series

Sinonasal OsS a : 14/35 b

Bouaoud

2019 4

Retrospective case series

RFS

1. Neoadjuvant chemotherapy confers no benefit in patients affected by craniofacial high-grade OsS 2. 3-year RFS: 76% 3. Eight (22.9%) deaths, seven cancer related 1. Radiological and pathological diagnosis alongside with adequate surgical resection are the most critical aspects in craniofacial OsS 2. 5-year OS: 75%–80% c ; 5-year RFS: 50%–60% c ; six (28.6%) local recurrences; one (4.8%) distant recurrence 1. Negative-margin resection and multimodality treatment are essential to improve outcomes 2. 5-year RFS: 47.6%; two (14.3%) local recurrences; six (42.9%) distant recurrences 75 years of age who undergo surgery for high-grade or intermediate-grade craniofacial OsS, (neo)adjuvant chemotherapy is indicated as it decreases the risk for local recurrence 2. 5-year OS: 55%; 14 (18.2%) local recurrences, seven (9.1%) local and distant recurrences, four (5.2%) distant recurrences 1. Postirradiation OsS in patients treated for NPC is associated with dismal prognosis 2. Surgery combined with postoperative chemotherapy could be a valuable treatment strategy 3. 1-, 2-, 3-, and 5-year OS: 53.3%, c 35.6%, c 13.5%, c and0%, c respectively 1. In patients younger than

et al. 1280

Sinonasal OsS a : 6/21 b (5, 2 sinonasal)

ElKordy

2018 4

Retrospective case series

1. OS 2. RFS

et al. 1278

Sinonasal OsS a : 5/14 b (0)

Krishnamurthy and

2018 4

Retrospective case series

RFS

Palaniappan 1279

Boonet al. 1276

Sinonasal OsS a : 38/77 b (19)

2016 4

Retrospective case series

OS

Liaoet al. 1277

Sinonasal OsS a : 33/45 b (45)

2016 4

Retrospective case series

OS

(Continues)